Participated · Series A · Jun 2026

BeeX develops autonomous underwater drones designed to perform recurrent, regulation-compliant inspections that are cheaper than conventional methods. Its drones have been deployed across Asia-Pacific and Europe to serve offshore wind, oil and gas, subsea cable operators and coastal infrastructure managers. The company also pursues defence applications, including a partnership with Singapore’s Ministry of Defence for national security uses. BeeX is headquartered in Singapore and focuses on expanding operational reach and technological capabilities to meet commercial and defence demand. The recent US$7.7 million Series A will fund fleet expansion and further capability development.

Led · Equity · Dec 2025

Spanish startup bound4blue designs and manufactures eSAIL®, a thick-profile, suction-assisted rigid sail that provides auxiliary wind propulsion for maritime vessels. Independently verified trials show fuel and emission reductions of 15–20 % on Odfjell’s Bow Olympus, with peaks up to 40 %, and daily fuel savings of up to 5.4 t on the Ville de Bordeaux ro-ro ship. The company has already installed its sails on seven ships and holds orders for twelve more, representing more than 50 eSAIL units. Customers include Maersk Tankers, Eastern Pacific Shipping, Odfjell, Klaveness Combination Carriers and BW Epic Kosan. With parallel production lines planned in Spain and China, bound4blue aims to manufacture several hundred sails annually and projects annual CO₂ savings exceeding 400,000 t by 2027. The newly raised capital positions the firm to transition from technology validation to full industrial scale-up while continuing R&D on additional wind-propulsion solutions.

Led · Series A · Aug 2024

Kreedo Early Childhood Solutions partners with affordable private schools and preschools to transform early childhood education through a play-based curriculum. Its core product is the 6T learning framework delivered via Kreedo Activity Labs, which integrates toys, technology, theory, teacher training, a timetable and teamwork for children aged 3–8, aligned with NEP 2020. The company also offers Practico, a digital home learning platform, and runs a specialised pre-primary teacher training franchise program. With new funding, Kreedo plans to expand into additional regions across India, extend offerings to Grades 3–5, and enhance Practico. Founded in 2012 by Mridula Shridhar and VK Manikandan and based in Bengaluru, Kreedo focuses on democratising early education through scalable partnerships. Over the past two years the company says it has doubled revenue, grown from 700 to 1,700 schools and preschools, and increased the number of children served from 55,000 to more than 140,000.

Led · Equity · Jul 2024

The Gentle Group provides food solutions and care services for patients with swallowing difficulties. The article describes it as a local social enterprise operating in Singapore. Its core offerings focus on tailored nutrition and care to address swallowing-related needs. The company recently attracted external capital via a reported investment round. The article does not include operating metrics, founding year, or other operational details.

Participated · Series A · Jun 2022

Tessa Therapeutics is focused on developing autologous CD30-CAR-T therapy (TT11) and an allogeneic CD30.CAR EBVST platform (TT11X) to treat CD30-positive lymphomas and other cancers. The company plans to use recent financing to advance clinical development of TT11 and TT11X and to support manufacturing at its newly qualified commercial cGMP facility. TT11’s pilot Phase 2 CHARIOT data presented at ASH showed a complete response (CR) rate of 57.1% and an overall response rate (ORR) of 71.4% in relapsed or refractory classical Hodgkin lymphoma; TT11 has received RMAT designation from the FDA and PRIME designation from the EMA. TT11X, the allogeneic EBVST-based program, reported clinical responses in seven of nine patients in a Phase 1 study, including four complete disappearances of tumor. Tessa intends to progress TT11 to a pivotal Phase 2 CHARIOT trial and advance TT11X, with the long-term goal of expanding its platforms to treat a broader range of cancers. The company operates a state-of-the-art manufacturing facility and is headquartered in Singapore. Tessa Therapeutics is a Singapore-based international clinical-stage biopharmaceutical company focused on T cell therapy for solid tumors. Its core product is a Virus Specific T cell (VST) platform that produces VSTs through a selective expansion process enabling them to infiltrate and survive in solid tumors. Tessa says its VSTs migrate to tumor sites and kill cancer cells while leaving healthy cells unharmed, which it cites as a key differentiator to other cell therapies. Led by co-founder and CEO Andrew Khoo, the company is conducting a multi-center Phase III trial targeting nasopharyngeal cancer and a Phase I trial targeting cervical and oropharyngeal cancers. Tessa completed an $80M financing round led by Temasek, and intends to use the proceeds to further advance its clinical pipeline and bring new therapies into clinical trials. Investors in the round included EDBI, Karst Peak Capital, Heliconia, Heritas and others.